EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 38 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin August 18, 2025 EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin February 14, 2025 The link between Down syndrome and childhood leukaemia September 1, 2022 Cómo compartir los resultados de las pruebas genéticas con la familia March 22, 2022 Load more HOT NEWS Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... Combining existing drugs improves prostate cancer survival EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical...
